- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00533039
sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial (SPIDER-PCI)
sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial
As evidence accumulates that atherogenesis or Coronary Artery Disease (CAD) may not be simply a disorder of lipid metabolism, but an inflammatory disease, the focus of treatment has shifted. A-002 or Varespladib is an anti-inflammatory drug for treatment of chronic and acute diseases. It acts by inhibiting secretory phospholipase A2 (sPLA2 ) - one of a family of enzymes leading to inflammation - which may be important in: 1) the development of atherosclerosis and 2) the increase in occurence of cardiovascular events after angioplasty. Previous studies have demonstrated that sPLA2: 1) facilitates the pro-atherogenic effects of low-density (LDL or bad cholesterol) and 2) increased levels post-angioplasty correlate with an increased risk of events at followup contact. Therefore this study proposes to investigate the ability of A-002 to prevent or reduce myocardial damage after angioplasty by inhibiting the cascade of inflammatory mediators.
Substudy - Subjects who agree will also have a vascular ultrasound 24h post-PCI to assess endothelial function.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Tissue injury after angioplasty is likely due to micro-emboli from mechanical trauma to a thrombotic lesion during angioplasty. In response to the ischemia sPLA2, possibly localized within atherosclerotic vascular tissue as well as from macrophages and monocytes, is released. Following ischemia-induced release, sPLA2 can bind to ischemically challenged cardiomyocytes and adversely affect their survival either directly through toxic effects on cardiomyocytes or indirectly by facilitating inflammation. It may be possible through sPLA2 inhibition to salvage non-lethally jeopardized cells following an ischemic episode thereby reducing the infarcted area and amount of tissue damage. Previous studies in patients with unstable angina support this hypothesis, and conclude that sPLA2 levels can be used to predict clinical outcomes. We hypothesize that sPLA2 inhibition with A-002 will reduce myocardial injury post-angioplasty.
Substudy - Peripheral vascular ultrasound should be done prior to receiving study drug and 24h post-PCI. Coronary endothelial function will be assessed at the time of PCI.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2C4
- Toronto General Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Men or women ≥ 18 years of age undergoing elective PCI, with or without stenting
Exclusion Criteria:
- ST elevation MI or any troponin elevation (non-STEMI) within preceding 10days
- Elevation of CK-MB or troponin I at baseline
- Recent (4 weeks) coronary bypass surgery
- NYHA class III-IV heart failure
- Left ventricular ejection fraction < 0.30
- Severe valvular heart disease
- Chronic inflammatory disease (e.g., lupus, rheumatoid arthritis, inflammatory bowel disease), or patients receiving steroid drugs
- Presence of severe liver disease with cirrhosis
- Recent active hepatitis
- Active chronic hepatitis
- ALT or AST > 3 × upper limit of normal (ULN)
- Biliary obstruction with hyperbilirubinemia (total bilirubin > 2 × ULN)
- Moderate or severe renal impairment (creatinine > 1.5 × ULN)
- Nephrotic syndrome or subjects undergoing dialysis
- Uncontrolled diabetes (HbA1c > 11% 1 month prior to screening)
- Initiation of statin therapy within 30 days
- Inability to provide consent.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Control
Subjects take 2 tablets BID.
Placebo tablets are identical to active medication.
|
250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
|
Experimentell: Varespladib (A-002)
Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
|
250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
The primary endpoint will be incidence of myocardial injury as evidenced by elevation of CK-MB or troponin I above the upper limit of normal.
Tidsram: 8 hours and 18-24 hours post-angioplasty
|
8 hours and 18-24 hours post-angioplasty
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
A secondary endpoint will be occurrence of elevation of CK-MB or troponin I above the upper limit of normal.
Tidsram: 8 and 18-24 hours post-angioplasty
|
8 and 18-24 hours post-angioplasty
|
A secondary endpoint will be occurrence of any major adverse cardiac events (MACE).
Tidsram: 30 days post-angioplasty
|
30 days post-angioplasty
|
A secondary outcome will be serum sPLA2 activity.
Tidsram: 5-7 days post-angioplasty
|
5-7 days post-angioplasty
|
Samarbetspartners och utredare
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SPIDER001
- A Sub-study of SPIDER-PCI
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kranskärlssjukdom
-
IRCCS Policlinico S. DonatoRekryteringAnomalous aortic origin of the coronary artery (AAOCA)Italien
-
Biotronik AGAvslutadde Novo Lesions in Native coronary arteriesNederländerna, Schweiz, Tyskland, Belgien
-
University Hospital OstravaRekryteringIn-Stent Carotis Artery RestenosisTjeckien
-
Stanford UniversityIndragenPopliteal Artery Entrapment Syndrome | Funktionell popliteal artery Entrapment SyndromeFörenta staterna
-
Osaka General Medical CenterAvslutadEmergent coronary procedurJapan
-
Sohag UniversityHar inte rekryterat ännuUmblical Artery Doppler under terminsgraviditetEgypten
-
Xiangya Hospital of Central South UniversityWest China Hospital; Henan Provincial People's Hospital; Renmin Hospital... och andra samarbetspartnersRekryteringSpontan isolerad Superior Mesenteric Artery DissektionKina
-
Inova Health Care ServicesBoston Scientific CorporationAvslutadKoronar angiografi | Transradiell åtkomst | Radiell artär Intimal mediala tjocklek | Distal Radial Artery Access (dTRA)Förenta staterna
-
University Hospital, AngersRekryteringPopliteal artär infångningFrankrike
-
Baylor College of MedicineAvslutadLungblödning | MAPCA - Major Aortopulmonary Collateral ArteryFörenta staterna
Kliniska prövningar på placebo
-
SamA Pharmaceutical Co., LtdOkändAkut bronkit | Akut övre luftvägsinfektionKorea, Republiken av
-
National Institute on Drug Abuse (NIDA)AvslutadAnvändning av cannabisFörenta staterna
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAvslutadManliga försökspersoner med typ II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAvslutadFarmakokinetik | SäkerhetsfrågorStorbritannien
-
Regado Biosciences, Inc.AvslutadFrisk volontärFörenta staterna
-
Texas A&M UniversityNutraboltAvslutadGlucose and Insulin Response
-
Longeveron Inc.AvslutadHypoplastiskt vänsterhjärtsyndromFörenta staterna
-
ItalfarmacoAvslutadBeckers muskeldystrofiNederländerna, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AvslutadVassleproteintillskott associerat med motståndsträning på hälsoindikatorer hos tränade äldre kvinnorFriska | Kroppssammansättning